Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-high trading volume on Wednesday . Approximately 9,503 shares were traded during trading, an increase of 117% from the previous session’s volume of 4,372 shares.The stock last traded at $17.80 and had previously closed at $18.45.

Wall Street Analysts Forecast Growth

AAPG has been the subject of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company has a fifty day simple moving average of $23.01 and a 200-day simple moving average of $25.64.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million during the quarter. As a group, equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently added to or reduced their stakes in the stock. UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. XY Capital Ltd lifted its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at $383,000. Finally, ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.